# A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

> **NCT02202161** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 70 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GSK2330672
- **DRUG:** Placebo
- **DRUG:** Sitagliptin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02202161
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-27
- **Primary completion:** 2015-01-30
- **Final completion:** 2015-01-30
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02202161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02202161, "A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02202161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*